Early recurrence in standard-risk medulloblastoma patients with the common idic(17)(p11.2) rearrangement

Neuro-Oncology

Volumn 14, Issue 7, 2012, Pages 831-840

  Bien Willner, Gabriel A ^a   Lpez Terrada, Dolores ^a   Bhattacharjee, Meena B ^b   Patel, Kayuri U ^b   Stankiewicz, Pawe ^b   Lupski, James R ^b   Pfeifer, John D ^a   Perry, Arie ^c  

^a WASHINGTON UNIVERSITY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FISH; i17q; idic(17)(p11.2); medulloblastoma; pediatric oncology

Indexed keywords

ARTICLE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CHROMOSOME 17; CHROMOSOME 17P; CHROMOSOME 17Q; CHROMOSOME REARRANGEMENT; DISEASE FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ISOCHROMOSOME; KARYOTYPE; MAJOR CLINICAL STUDY; MEDULLOBLASTOMA; METASTASIS; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; TELOMERE;

ADOLESCENT; ADULT; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 17; COHORT STUDIES; FEMALE; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; ISOCHROMOSOMES; MALE; MEDULLOBLASTOMA; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RISK FACTORS; SURVIVAL RATE; YOUNG ADULT;

EID: 84862866448     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos086     Document Type: Article

References (50)

1. Gurney JG, Smith MA, Bunin GR. CNS and miscellaneous intracranial and intraspinal neoplasms. In: Reis, LAG, Smith, MA, Gurney, JG, et al., eds. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. Vol NIH Pub. No. 99-4649. Bethesda, MD: National Cancer Research Institute Cancer Surveillance Research Program, NIH Pub. No. 99-4649; 1999:51-63.
2. Gurney JG, Kadan-Lottick N. Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol. 2001;13(3):160-166. (Pubitemid 32433971)
3. Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24(25):4202-4208. (Pubitemid 46622300)
4. Packer RJ, Sutton LN, Elterman R, et al. Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurg. 1994;81(5):690-698. (Pubitemid 24328694)
5. Polkinghorn WR, Tarbell NJ. Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol. 2007;4(5):295-304. (Pubitemid 46758787)
6. Garre ML, Cama A, Bagnasco F, et al. Medulloblastoma variants: agedependent occurrence and relation to Gorlin syndrome-a new clinical perspective. Clin Cancer Res. 2009;15(7):2463-2471.
7. Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer. 2002;94(2):552-560. (Pubitemid 34081387)
8. Perry A. Medulloblastomas with favorable versus unfavorable histology: how many small blue cell tumor types are there in the brain? Adv Anat Pathol. 2002;9(6):345-350.
9. Brown HG, Kepner JL, Perlman EJ, et al. "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study. J Neuropathol Exp Neurol. 2000;59(10):857-865.
10. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123(4):465-472.
11. Grotzer MA, Hogarty MD, Janss AJ, et al. MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res. 2001;7(8):2425-2433. (Pubitemid 32751645)
12. Gilbertson R, Wickramasinghe C, Hernan R, et al. Clinical and molecular stratification of disease risk in medulloblastoma. Br J Cancer. 2001;85(5):705-712. (Pubitemid 32929469)
13. Bayani J, Zielenska M, Marrano P, et al. Molecular cytogenetic analysis of medulloblastomas and supratentorial primitive neuroectodermal tumors by using conventional banding, comparative genomic hybridization, and spectral karyotyping. J Neurosurg. 2000; 93(3):437-448.
14. Eberhart CG, Burger PC. Anaplasia and grading in medulloblastomas. Brain Pathology. 2003;13(3):376-385. (Pubitemid 36975828)
15. Ellison DW, Kocak M, Dalton J, et al. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol. 2010;29(11):1400-1407.
16. Pfister S, Remke M, Benner A, et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. J Clin Oncol. 2009;27(10):1627-1636.
17. Scheurlen WG, Schwabe GC, Joos S, Mollenhauer J, Sorensen N, Kuhl J. Molecular analysis of childhood primitive neuroectodermal tumors defines markers associated with poor outcome. J Clin Oncol. 1998;16(7):2478-2485. (Pubitemid 28309044)
18. Nicholson J, Wickramasinghe C, Ross F, Crolla J, Ellison D. Imbalances of chromosome 17 in medulloblastomas determined by comparative genomic hybridisation and fluorescence in situ hybridisation. Mol Pathol. 2000;53(6):313-319.
19. Cogen PH, McDonald JD. Tumor suppressor genes and medulloblastoma. J Neurooncol. 1996;29(1):103-112. (Pubitemid 26193509)
20. Biegel JA, Rorke LB, Packer RJ, et al. Isochromosome 17q in primitive neuroectodermal tumors of the central nervous system. Genes, Chromosomes & Cancer. 1989;1(2):139-147. (Pubitemid 20094558)
21. Emadian SM, McDonald JD, Gerken SC, Fults D. Correlation of chromosome 17p loss with clinical outcome in medulloblastoma. Clin Cancer Res. 1996;2(9):1559-1564. (Pubitemid 126447450)
22. Leonard JR, Cai DX, Rivet DJ, et al. Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features. J Neurosurg. 2001;95(1):82-88. (Pubitemid 32799776)
23. Pan E, Pellarin M, Holmes E, et al. Isochromosome 17q is a negative prognostic factor in poor-risk childhood medulloblastoma patients. Clin Cancer Res. 2005;11(13):4733-4740. (Pubitemid 41557192)
24. Giordana MT, Migheli A, Pavanelli E. Isochromosome 17q is a constant finding in medulloblastoma. An interphase cytogenetic study on tissue sections. Neuropathol Appl Neurobiol. 1998;24(3):233-238. (Pubitemid 28334091)
25. Scheurlen WG, Schwabe GC, Seranski P, et al. Mapping of the breakpoints on the short arm of chromosome 17 in neoplasms with an i(17q). Genes, Chromosomes & Cancer. 1999;25(3):230-240. (Pubitemid 29266692)
26. McCabeMG, Ichimura K, Liu L, et al.High-resolution array-based comparative genomic hybridization ofmedulloblastomas and supratentorial primitive neuroectodermal tumors. JNeuropathol ExpNeurol. 2006;65(6):549-561. (Pubitemid 44288939)
27. Mendrzyk F, Korshunov A, Toedt G, et al. Isochromosome breakpoints on 17p in medulloblastoma are flanked by different classes of DNA sequence repeats. Genes, Chromosomes & Cancer. 2006;45(4):401-410. (Pubitemid 43346772)
28. Carvalho CM, Lupski JR. Copy number variation at the breakpoint region of isochromosome 17q. Genome Res. 2008;18(11):1724-1732.
29. Shaw CJ, Lupski JR. Implications of human genome architecture for rearrangement-based disorders: the genomic basis of disease. Hum Mol Genet. 2004;13 Spec No 1:R57-R64. (Pubitemid 38443799)
30. Barbouti A, Stankiewicz P, Nusbaum C, et al. The breakpoint region of the most common isochromosome, i(17q), in human neoplasia is characterized by a complex genomic architecture with large, palindromic, low-copy repeats. Am.J. Human Genetics. 2004;74(1):1-10. (Pubitemid 38085233)
31. McCabe MG, Ichimura K, Pearson DM, et al. Novel mechanisms of gene disruption at the medulloblastoma isodicentric 17p11 breakpoint. Genes, Chromosomes & Cancer. 2009;48(2):121-131.
32. Fioretos T, Strombeck B, Sandberg T, et al. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations. Blood. 1999;94(1):225-232. (Pubitemid 29300153)
33. Gilbertson RJ, Ellison DW. The origins of medulloblastoma subtypes. Annu Rev Pathol. 2008;3:341-365. (Pubitemid 351488285)
34. Squire SE, Chan MD, Marcus KJ. Atypical teratoid/rhabdoid tumor: the controversy behind radiation therapy. J Neurooncol. 2007;81(1):97-111. (Pubitemid 44963996)
35. Grill J, Sainte-Rose C, Jouvet A, et al. Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. Lancet Oncol. 2005;6(8):573-580. (Pubitemid 41051935)
36. Jakacki RI, Feldman H, Jamison C, Boaz JC, Luerssen TG, Timmerman R. A pilot study of preirradiation chemotherapy and 1800 cGy craniospinal irradiation in young children with medulloblastoma. Int J Radiat Oncol Biol Phys. 2004;60(2):531-536. (Pubitemid 39233474)
37. Ellison DW, Dalton J, Kocak M, et al. Medulloblastoma: clinicopathological correlates of SHH, Wnt, and non-SHH/Wnt molecular subgroups. Acta Neuropathol. 2011;121(3):381-396.
38. Northcott PA, Korshunov A,Witt H, et al.Medulloblastomacomprises four distinct molecular variants. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2011;29(11):1408-1414.
39. Fuller CE, Perry A. Fluorescence in situ hybridization (FISH) in diagnostic and investigative neuropathology. Brain Pathol. 2002;12(1):67-86. (Pubitemid 33131364)
40. Bien-Willner GA, Stankiewicz P, Lupski JR, Northup JK, Velagaleti GV. Interphase FISH screening for the LCR-mediated common rearrangement of isochromosome 17q in primary myelofibrosis. Am. J. Hematology. 2005;79(4):309-313. (Pubitemid 41098846)
41. Abramoff MD, Magelhaes PJ, Ram SJ. Image Processing with ImageJ. Biophotonics International. 2004;11(7):36-42.
42. Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. J Clin Oncol. 2003;21(8):1581-1591. (Pubitemid 46594113)
43. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7(10):813-820. (Pubitemid 44464063)
44. Zeltzer PM, Boyett JM, Finlay JL, et al. Metastasis stage, adjuvant treatment, and residual tumor are prognostic factors for medulloblastoma in children: conclusions from the Children's Cancer Group 921 randomized phase III study. J Clin Oncol. 1999;17(3):832-845. (Pubitemid 29109313)
45. Ellison D. Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathology and Applied Neurobiology. 2002;28(4):257-282. (Pubitemid 34989289)
46. Lafay-Cousin L, Bouffet E, Hawkins C, Amid A, Huang A, Mabbott DJ. Impact of radiation avoidance on survival and neurocognitive outcome in infant medulloblastoma. Curr Oncol. 2009;16(6):21-28.
47. Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW. Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res. 2004;10(16): 5482-5493. (Pubitemid 39100486)
48. Eberhart CG, Tihan T, Burger PC. Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol. 2000;59(4):333-337. (Pubitemid 30183701)
49. Pietsch T,Waha A, Koch A, et al. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res. 1997;57(11):2085-2088. (Pubitemid 27247016)
50. Koch A, Waha A, Tonn JC, et al. Somatic mutations of Wnt/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer. 2001;93(3):445-449. (Pubitemid 32592067)